青春期异常性关节炎中甲素不耐受:定义,风险和管理
Camilla Wibrand1, Nini Kyvsgaard1, Troels Herlin2
1Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
Paediatric drugs
|July 23, 2024
概括
青春期异常性关节炎 (JIA) 是常见的,但甲状腺素治疗经常因不耐受性而受到干扰. 本综述考察了JIA的甲状腺素不耐受性风险因素和管理策略.
科学领域:
- 类风湿病学 类风湿病学
- 儿科 儿科 儿科
- 药理学 药理学是指药理学的学科.
背景情况:
- 青少年异常性关节炎 (JIA) 是儿童类风湿性疾病的主要原因,可能导致残疾.
- 甲托雷克萨特是JIA的主要治疗方法,但不耐受性经常会扰乱治疗.
- 不耐受症的症状包括恶心,吐和行为问题,影响治疗的坚持.
研究的目的:
- 审查JIA中甲状腺素不耐受症的鉴定和评估.
- 评估潜在的风险因素,遗传关联,以及对甲状腺素不耐受症的管理策略.
- 强调需要就结果测量和报告在JIA甲状腺素不耐受性研究中达成共识.
主要方法:
- 关于青少年异常性关节炎中甲状腺素不耐受性研究的文献综述.
- 分析建议的风险因素:性别,年龄,疾病活动,治疗参数,遗传学和心理因素.
- 评估当前和潜在的管理策略,以治疗甲状腺素不耐受.
主要成果:
- 甲基酸不耐受是有效的JIA管理的一个重要障碍.
- 关于风险因素存在矛盾的发现,需要进一步的研究.
- 遗传和心理因素是相关的,但需要更多的调查.
- 目前还缺少标准化的结果指标和报告.
结论:
- 甲甲酸不耐受会显著影响JIA的治疗,需要更好的理解和管理.
- 需要进一步的研究来澄清风险因素和遗传关联.
- 建立对结果措施的共识对于推进JIA甲状腺素不耐受性研究和临床实践至关重要.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
01:29Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
126
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
126
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
110
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
110
01:29Pulmonary Tuberculosis I
228
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
228
01:19Antiasthma Drugs: Leukotriene Modifiers
269
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
269